Core Viewpoint - Optimi Health Corp. is implementing equity compensation and marketing initiatives to support its growth strategy and enhance market awareness [1] Equity Incentive Grants - The company has approved the grant of 850,000 stock options and 555,000 restricted share rights to directors, officers, employees, and key individuals [2] - The stock options are exercisable for five years at an exercise price of $0.50 per common share, while the restricted share rights will convert into common shares without additional consideration [3] Marketing and Sponsored Research Initiatives - Optimi has entered into a research sponsorship agreement with Diamond Equity Research LLC to provide independent research coverage, including an initiation report and financial valuation model [4] - Research coverage will be distributed through various financial and social media platforms such as FactSet, LinkedIn, Yahoo Finance, and Google Finance [5] Marketing and Investor Awareness Services - The company has engaged Native Ads Inc. for investor awareness and promotional services, with a digital media campaign set to begin in Q1 2026 and last up to 24 months [6] - A budget of up to US$350,000 has been approved for the digital advertising campaign aimed at increasing awareness of the company's MDMA and psilocybin products [7][8] Company Overview - Optimi Health Corp. is a GMP-compliant pharmaceutical drug manufacturer licensed by Health Canada, operating from two facilities in British Columbia [9]